Assembly Bio Exercises Profit-Share Option on Gilead Herpes Program, Secures $75M Payment
ASMB sits 78% above its 52-week low of $20.23.
Summary
Assembly Biosciences exercised its option to share 40% of U.S. development costs and profits for the helicase-primase inhibitor program targeting recurrent genital herpes under its Gilead collaboration. The decision follows review of Gilead's development plan and budget, and triggers a $75 million option continuation payment expected in Q4, extending cash runway into 2029. Gilead retains sole development and commercialization rights, with GS-1179 expected to enter phase 2 by year-end. Assembly Bio remains eligible for up to $280 million in regulatory/commercial milestones plus tiered royalties ex-U.S., with potential conversion to up to $330 million in milestone payments and royalties. This is a material positive for ASMB, validating the program's prospects and adding non-dilutive capital. GILD is less directly affected as the collaboration partner.
At the time of this announcement, ASMB was trading at $36.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $718.3M. The 52-week trading range was $20.23 to $39.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.